Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMIZE: Telaprevir BID vs q8h in Genotype 1 Chronic HCV
NCT01241760Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Dec 2010
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of telaprevir in hepatitis C (HCV) (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Sustained Virologic Response 12 Weeks After Last Planned Dose. Started Dec 2010; status: completed.
02
Drugs
telaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01241760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01241760.